Company Encyclopedia
View More
name
Adverum Biotech
ADVM.US
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing BGTF-027 (AAV.7m8-L-opsin), a novel gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy. Adverum Biotechnologies, Inc.
1.902 T
ADVM.USMarket value -Rank by Market Cap -/-

Financial Score

13/12/2025 Update
E
BiotechnologyIndustry
Industry Ranking0/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-417.79%E
    • Profit Margin0.00%D
    • Gross Margin0.00%E
  • Growth ScoreE
    • Revenue YoY-100.00%E
    • Net Profit YoY-55.73%D
    • Total Assets YoY-69.11%E
    • Net Assets YoY-138.62%E
  • Cash ScoreD
    • Cash Flow Margin0.00%D
    • OCF YoY-100.00%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreE
    • Gearing Ratio176.87%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    CEO Fischer Acquires 650,000 Of Adverum Biotechnologies Inc [ADVM]

    Fischer Laurent Chief Executive Officer of Adverum Biotechnologies Inc [ADVM] filed a Form 4 on December 10, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date12/9/25TransactionExerciseShares650,000Price$0.97Value$629,980Ending Holdings: 0 - DirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    ADVM
    0.00%
    Reuters·
    US
    ADVM
    0.00%

    CFO Rubinstein Acquires 90,750 Of Adverum Biotechnologies Inc [ADVM]

    Rubinstein Linda M Chief Financial Officer of Adverum Biotechnologies Inc [ADVM] filed a Form 4 on December 10, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date12/9/25TransactionExerciseShares90,750Price$2.26Value$204,750Ending Holdings: 0 - DirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    ADVM
    0.00%
    Reuters·
    US
    ADVM
    0.00%

    Adverum Biotechnologies (NASDAQ:ADVM) CEO Buys $47,000.40 in Stock

    Adverum Biotechnologies CEO Laurent Fischer bought 11,085 shares, increasing his position by 15.22%. The purchase was at $4.24 per share, totaling $47,000.40. Fischer now owns 83,899 shares valued at $355,731.76. The transaction was disclosed in an SEC filing. Adverum's stock traded at $4.36, with a market cap of $96.26 million. Analysts have mixed ratings, with a consensus "Hold" and a price target of $10.50. The company develops gene therapy for ocular diseases, with its lead candidate in phase 2 trials.

    Market Beat·
    US
    ADVM
    0.00%
    Market Beat·
    US
    ADVM
    0.00%

    Adverum Biotechnologies (NASDAQ:ADVM) COO Purchases $211,000.00 in Stock

    Adverum Biotechnologies' COO, Peter Soparkar, purchased 50,000 shares of the company's stock for $211,000, increasing his position by 165.62%. The stock purchase was disclosed in an SEC filing. Following the transaction, Soparkar owns 80,189 shares valued at approximately $338,398. The company's stock rose 2.3% to $4.36. Analysts have mixed ratings on the stock, with a consensus rating of 'Hold' and an average target price of $10.50. Institutional investors hold 48.17% of the company's stock.

    Market Beat·
    US
    ADVM
    0.00%
    Market Beat·
    US
    ADVM
    0.00%

    Adverum Biotechnologies Executives Increase Stake in Company

    Adverum Biotechnologies executives Laurent Fischer and Peter Soparkar have increased their stakes in the company. Fischer, CEO and President, purchased 128,699 shares for $553,916, raising his ownership to 201,513 shares. Soparkar, COO, acquired 50,000 shares for $211,000, increasing his stake to 80,189 shares. These transactions occurred on December 5 and 8, 2025, at average prices of $4.24 and $4.31 per share.

    TradingView·
    US
    ADVM
    0.00%
    TradingView·
    US
    ADVM
    0.00%
    © 2025 Longbridge｜Disclaimer